CI
Enhanced Filtering
Recent Real-Time Alerts
FDA grants priority review for Competitor X's new multiple myeloma therapy
30m ago • Oncology • Multiple Myeloma
Positive Phase 3 results for Competitor Y's IL-23 inhibitor in psoriatic arthritis
1h ago • Immunology • Psoriatic Arthritis
New publication in NEJM on long-term safety of TREMFYA in psoriasis
3h ago • Immunology • Psoriasis
Latest Data Snacks
Multiple Myeloma Treatment Landscape
Analysis of DARZALEX positioning in the evolving multiple myeloma treatment landscape.
Oncology
Market Landscape
Psoriatic Arthritis Competitive Landscape
Analysis of TREMFYA positioning in the psoriatic arthritis market.
Immunology
Competitive Positioning
Treatment-Resistant Depression Market
Analysis of SPRAVATO adoption trends and reimbursement landscape.
Neurology
Market Landscape
Recent IR & Earnings
Pipeline Tracker Preview
View full tracker →| Company | Asset | Therapeutic Area | Disease | Phase | Start Date | Primary Completion | NCT Number |
|---|---|---|---|---|---|---|---|
| Pfizer | PF-06939926 | Rare Disease | Duchenne Muscular Dystrophy | Phase 3 | May 10, 2025 | Dec 15, 2027 | NCT05096221 |
| Novartis | LNP023 | Immunology | IgA Nephropathy | Phase 3 | Apr 22, 2025 | Nov 30, 2026 | NCT05144321 |
| Johnson & Johnson | JNJ-63723283 | Oncology | Multiple Myeloma | Phase 2 | May 5, 2025 | Jun 15, 2026 | NCT05123456 |
RSS Feed Manager Preview
Manage all feeds →ClinicalTrials.gov - Breast Cancer
Feeder.coTracking new and modified breast cancer trials (Phase 1-3, Industry sponsored)
Updated 30m ago
PubMed - Multiple Myeloma
Feeder.coTracking new publications related to multiple myeloma treatments
Updated 1h ago
Johnson & Johnson Press Releases
Feeder.coTracking all press releases from Johnson & Johnson
Updated 2h ago
© 2025 CI Agent. All rights reserved.